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Abstract: The generation of bioactive molecules from inactive
precursors is a crucial step in the chemical evolution of life,
however, mechanistic insights into this aspect of abiogenesis are
scarce. Here, we investigate the protein-catalyzed formation of
antivirals by the 3C-protease of enterovirus D68. The enzyme
induces aldol condensations yielding inhibitors with antiviral
activity in cells. Kinetic and thermodynamic analyses reveal
that the bioactivity emerges from a dynamic reaction system
including inhibitor formation, alkylation of the protein target
by the inhibitors, and competitive addition of non-protein
nucleophiles to the inhibitors. The most active antivirals are
slowly reversible inhibitors with elongated target residence
times. The study reveals first examples for the chemical
evolution of bio-actives through protein-catalyzed, non-enzy-
matic C@C couplings. The discovered mechanism works under
physiological conditions and might constitute a native process
of drug development.
Introduction
According to Oparin and Haldane, the chemical evolution
of life began with the formation of its chemical building
blocks,[1] and considerable progress has been made in explain-
ing the prebiotic generation of sugars,[2] amino acids,[3] and
nucleosides.[4] Formation of lifeQs building blocks, however,
does not rationalize the generation and selection of func-
tional, bioactive molecules, which are required to develop
complex features of living systems including metabolism,
compartmentalization, and replication.[5] Understanding the
mechanisms yielding functionally bioactive molecules will
provide insights into the emergence of the complex features
of life and thus is worth pursuing.
We hypothesize here that bioactive molecules can be
generated by a mechanism of chemical evolution involving
templated reactions embedded within a multidimensional
network of chemical reactivity or “dynamic reaction system”.
Reversible and irreversible protein-templated reactions have
been studied extensively, mostly in order to identify protein-
binding ligands.[6] Initially, proteins were demonstrated to
stabilize imines and hydrazones formed reversibly from
aldehydes, amines, and hydrazines.[7] These products have
been useful in dynamic ligation assays for the sensitized and
site-directed detection of low-affinity fragments and bioactive
fragment combinations.[8] Protein ligands were also formed
via irreversible, templated reactions using dipolar cycloaddi-
tions of azides with alkynes, or thioacids.[9] For protein-
catalyzed amidations, the mechanism and saturation kinetics
were established yielding fragment combinations with super-
additive affinity.[10] Recently, three-component Mannich liga-
tions catalyzed by the human transcription factor STAT5 were
discovered furnishing anti-leukemic drugs active in mice.[11]
Further templated multicomponent reactions were investi-
gated.[12,13] There have been, however, no reports of protein-
templated, native C@C couplings yet, although these reactions
are essential for the construction of many bioactive molecules
found in Nature.
In this paper, we study the chemical evolution of antivirals
through Knoevenagel condensations,[14] native C@C couplings
of the aldol type, catalyzed by the 3C protease of enterovirus
EV D68. We envisioned that the protease would be able to
activate aldehydes via hydrogen bonds inducing aldol reac-
tions with suitable C-nucleophiles. To test this hypothesis,
potential C-nucleophiles are screened in an enzyme activity
assay. Kinetics and thermodynamics of protein-templated
reactions are analyzed revealing a mechanism for the
chemical evolution of bioactive molecules in a dynamic
reaction system and providing insights into the mode of action
of cellularly active antivirals obtained by this approach.
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Results and Discussion
Enteroviral 3C proteases are validated drug targets in
enteroviral and rhinoviral infections,[15] being strictly selective
for substrates with glutamine (Gln) in P1-position. The same
applies to the 3C-like coronavirus main proteases.[16] Pepti-
domimetics such as rupintrivir (AG-7404) were developed as
potent inhibitors of 3C proteases, however, failed in advanced
clinical studies so far.[17] This failure might be due to the
comparably high molecular weight, limited bioavailability,
and reduced ability to cross biological membranes of peptide-
based inhibitors. Fragment-based inhibitors might overcome
these limitations and have shown broad-band activity toward
3C proteases.[8c] The 3C protease of enterovirus D68 (EV
D68) cleaves amide bonds at P1 by attacking the electrophilic
carbonyl carbon with the nucleophilic cysteine residue
(Cys147) of the active site. This attack is enabled through
the activation of the amide carbonyl by H-bond-donors
providing positive partial charge in the oxyanion hole.
Discovery of Protein-Catalyzed C@C Couplings
3-Formyl benzamide 1 has been reported as a moderately
active inhibitor of rhinovirus 3C protease, presumably due to
efficient biomimicry of the native glutamine residue.[18] We
hypothesized that binding of aldehyde 1 through an H-
bonding network might activate the electrophilic aldehyde
carbonyl for the addition of C-nucleophiles resulting in C@C
coupling reactions. This should be possible, if the active site
favors formation of the enol-tautomer of an enolizable
carbonyl fragment F and thus stabilizes a protein-bound
Zimmerman–Traxler transition state (Figure 1a).[19] Using the
crystal structure 3ZVG,[20] aldehyde 1 was docked into the
active site of EV D68 3C protease and a binding model was
derived (Figure 1b). In this, the primary amide of 1 bound to
the proteaseQs S1-pocket via two H-bonds with Thr142 and
one with the imidazole ring of His161. The aldehyde
functionality of 1 docked to the oxyanion hole, accepting H-
bonds from the backbone amides of Gly145 and Cys147. The
thiol of Cys147 was located closely to the carbonyl-carbon,
ready to attack forming a hemithioacetal intermediate.
For the testing of this hypothesis, 13 carbonyl fragments
(F1–F13) were selected for their potential to form enoles as
potent C-nucleophiles (Figure 1c). All 13 fragments were
inactive as inhibitors (Table S1). Then 2-formyl-benzamide
1 (IC50 = 48 mM) was incubated with EV D68 3C-protease at
a concentration resulting in 75% residual activity of the
enzyme. One of the carbonyl fragments was added per well
and the formation of active inhibitors was assayed with the
fluorogenic FRET substrate (Dabcyl-KTLEALFQGPPVY-
E(Edans)-amide) for read-out (Figure 1 d). After 2 h incuba-
tion, five of the 13 carbonyl fragments (F1, F4, F5, F6, and F8)
showed significantly increased inhibition of the protease (p<
0.05) in combination with aldehyde 1 compared to the
aldehyde alone. HPLC-QTOF-MS analysis confirmed the
formation of Knoevenagel condensation products in all assays
displaying significantly increased inhibition. Relative product
formation was quantified after 1 h reaction time at pH values
of 4, 6, 8, and 10 with and without the protein (10 mM) present
in the assay solution (Figure S1). The highest yields of C@C
coupling products were observed for fragment F1 at pH 8.0
Figure 1. Discovery of protein-catalyzed C@C couplings. a. Postulated Zimmerman–Traxler transition state of the aldol reaction of aldehyde 1 with
the E-enol tautomer of fragment F bound to EV D68 3C protease. b. Binding hypothesis of 3-formyl-benzamide 1 to EV D68 3C protease (3ZVG).
c. Enolizable fragments F1–F13. d. Fragment ligation assay of EV D68 3C protease with aldehyde 1 (19 mM) and fragments F1–F13 (19 mM) for
2 h. Activity of protease was determined using a fluorogenic FRET substrate (see text). e. Binding simulation of the presumed anti-aldol addition
product of 1 and F1. f. Covalent binding mode of the Knoevenagel condensation product 2. Color code: white balls—protein carbon atoms, grey
sticks—ligand carbon atoms, red balls and sticks—oxygen atoms, blue balls and sticks—nitrogen atoms, yellow balls—protein sulfur atom, red
and green arrows—hydrogen bond acceptors and donors, respectively, yellow spheres—lipophilic contacts.
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with almost 50%. The aldol addition product with fragment
F1, O-ethyl 2-cyano-acetate, fitted into the oxyanion hole of
the protease being coordinated by three bifurcated H-bonds
from the backbone amide NH groups of Gly145, Gln146, and
Cys147 to the beta-hydroxy and carbonyl-functionalities
(Figure 1e). H-bonds to the secondary hydroxy group might
stimulate the elimination of water from the aldol addition
product and thus furnish the alpha-beta-unsaturated ester as
condensation product 2 (Figure 1 f), which might react further
under Michael addition of the thiolate of Cys147 to the
double bond. Ketone fragments F4–F8 displayed protein-
dependent formation of the Knoevenagel products with
a maximum yield of ca. 20% for F4. pH-optimum was 8.0
for F4, F6, and F8, pH 6.0 for F5 and F7. Traces of product
(ca. 1%) were formed for F2 and F3 (at pH 10) and for F12
(at all pH values). As Knoevenagel products—according to
our initial hypothesis—were expected to be responsible for
the increased inhibition, they were re-synthesized and tested
as inhibitors of the EV D68 protease (Table 1). Indeed, most
condensation products of aldehyde 1 with enolizable carbonyl
compounds yielded potent inhibitors of the 3C protease.
The most potent inhibitors 2–6 with IC50 values between
0.46 and 2 mM were more than 100 times more potent than the
starting benzaldehyde 1. The strongest effect in the fragment
ligation assay was observed for fragment F4, 3-oxo-butane
nitrile. Thus, the kinetics of the protein-catalyzed formation
of the inhibitor from F4 and cyano-ketone 5 were determined.
At first, 100 mM aldehyde 1 and 100 mM of 3-oxo-butane
nitrile F4 were incubated with 10 mM of EV D68 protease or
without protein at 25 8C for 60 min of 5 was quantified by
HPLC-QTOF-MS (Figure 2a). Formation of 5 followed
saturation kinetics—typical for a protein-catalyzed and
product-inhibited reaction. Product concentrations over time
were fitted to an exponential saturation function c(t) = c0 +
(cmax@c0)(1@e^(@Kt)). The maximum concentration cmax was
12.6 mM (with c0 = 0) with a half reaction time (t1/2 = ln2/K) of
17 min. The reaction rate k0 = dc/dt at t0 was 0.51 mMmin
@1
indicating a 5-fold rate acceleration in comparison to the
uncatalyzed, non-templated background reaction
(0.1 mMmin@1). Reaction rates were reduced at lower con-
centrations of the cyano-ketone fragment F4 (10 or 50 mM)
yielding 12.2 mM (9.2 mM) of 5 with t1/2 of 115 min (25 min),
both with 10 mM protein (Figure 2b,c). A lower aldehyde
concentration (5 mM), 50 mM protein and 100 mM F4 gener-
ated 4.8 mM of product 5 with a t1/2 of 100 min and a back-
ground of < 0.5 mM (Figure 2d).
The antiviral activity of compounds 2–12 was determined
in HeLa cells infected with EV D68 (Table 1, Supporting
Information).[21] All compounds tested in the cellular assay
were non-toxic toward the host cells (CC50 > 100 mM) and
most of them were active as antivirals. Interestingly, for
several of the compounds, the antiviral activity in cells (EC50
value) deviated strongly from the inhibition in the enzyme
assay (IC50). To assign these deviations the relative antiviral
efficiency IC50/ EC50 was calculated for all inhibitors. Values
for the inhibition ratio ranged from 0.014 (low antiviral
efficiency) for compound 5 to 8.2 (high antiviral efficiency)
for inhibitor 12.
Investigating the Chemical and Biochemical Reactivity of
Antivirals
As the tested 3-vinyl-benzamides 2–13 displayed drasti-
cally different relative bioactivities, the next goal was to
understand, why this was the case. Realizing that several
chemical and biochemical reactions were involved in the
generation and variation of bioactivity, we decided to inves-
tigate the dynamic reaction system of three representative
inhibitors, 2, 5, and 12. For rationalization of their binding see
Figure S2. After studying the protein-catalyzed formation of
antivirals, we investigated the reversibility of the C@C
couplings with and without protein. While inhibitors 2 and 5
were stable in assay buffer with DTT, decomposition was
observed, if DTT was omitted from the buffer (Figure S3).
Retro-reactions of inhibitors 2 and 5 (20 mM) in buffer (pH 8)
with and without 10 mM of the protein were monitored by
HPLC-MS, recording the release of 3-formyl benzamide 1.
Cleavage of ketone 5 was significantly faster than that of
acrylate ester 2, displaying ca. 30 % decomposition of 5 after
30 min, while only 8% of 2 were cleaved at the same time. In
both cases, the retro-aldol reaction was pH-dependent and
Table 1: Inhibitors of the 3C protease of enterovirus D68 formed through
Knoevenagel condensations of 1 with F1-F11, their antiviral effect in cells
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there was no reaction at pH 4, suggesting the addition of
water as the primary step of the cleavage. Decomposition was
not accelerated by the protease, excluding a protein-catalyzed
retro-aldol reaction. Instead the protein reduced the rate of
the cleavage reaction slightly, however, without efficiently
protecting the inhibitors against decomposition. Even more
rapid decomposition was observed for the Knoevenagel
products from stronger acidic C-nucleophiles including bar-
bituric acid, 2-(methyl-sulfonyl)-acetonitrile, and 2-nitro-
acetonitrile. In these cases, addition of water and retro-aldol
reaction occurred already during synthesis and work-up.
Other inhibitors including diester 12 and cyano-amides (3,4)
did not decompose via a retro-aldol mechanism.
Next, reactions of the inhibitors with the protease were
investigated. Cyano-ester 2 displayed a linear turnover of the
substrate enzyme inhibition assay typical for reversible
inhibitors (Figure 3 a). In contrast, cyano-ketone 5 and diester
12 showed small but visible time-dependent rate reduction at
higher inhibitor concentrations, which could indicate irrever-
sible inhibition of the substrate turnover.[22] Dilution assays
were conducted to analyze the subtle differences more clearly
(Figure 3b). For this, the enzyme was inhibited completely at
the 20-fold IC50-concentration of the inhibitor and then
diluted by the factor of 100 prior to addition of the substrate.
In the case of inhibitor 2 the activity of the enzyme was
instantaneously and fully restored, for inhibitors 5 and 12 the
recovery was also rapid but only partial (ca. 80%). These
results suggest that all three inhibitors 2, 5, and 12 act
reversibly, although 5 and 12 seem to inhibit the protease with
slower kinetics compared to inhibitor 2.
As these kinetic differences were suspected to be the key
to explain the observed cellular antiviral and enzymatic
activities, stabilities of the covalent enzyme-ligand complexes
were investigated by employing protein-mass spectrometry
(Figure 3c–e, Figure S4, S5). Protein-MS of EV D68 3C
protease was recorded and deconvoluted both in native MS in
ammonium formate buffer and under denaturing conditions
from acetonitrile-water. Inhibitors 2 and 5 showed no masses
of the protein-ligand complex in denaturing MS, suggesting
the rapid decomposition of the protein-ligand complex.
Reversible formation of the protein-inhibitor complexes with
2 and 5 was confirmed by native protein MS (Figure 3c,e).
Increasing concentrations of inhibitor 2 incubated with a fixed
protein concentration yielded a deconvoluted mass signal of
the protein-inhibitor complex with increasing intensity, which
was saturated with an apparent dissociation constant (KD) of
16 (+ /@2.4) mM. In contrast, inhibitor 12 displayed a protein-
ligand signal with > 80 % intensity in denaturing protein-MS
suggesting the slow decomposition of the protein-ligand
complex and a lower koff-rate (Figure 3d). In addition, the
protein-inhibitor complex of irreversible inhibitor O-ethyl 3-
carbamoyl-cinnamoyl ester 13 was digested with trypsin and
the binding site was identified by MS showing the complete
alkylation of the 13mer peptide containing Cys147 with
inhibitor 13 (Figure S6).
Another factor, which could have an impact on the
activity of the generated antivirals, are reactions of the
inhibitors with competing, non-protein nucleophiles in solu-
tion. Initially, IC50 values were recorded with dithiothreitol
(DTT), a reductant to maintain the activity of the 3C
Figure 2. Kinetic analysis of protein-catalyzed C@C couplings. Time-dependent formation of 5 at r.t. for 60–150 min with different concentrations
of F4, 1 and EV D68 3C. Quantification of 5 was conducted by HPLC-QToF-MS using a freshly recorded calibration curve. Time-dependent
concentration of 5 was fitted to the exponential saturation function c(t) = c0 + (cmax@c0)(1@e^(@Kt)). a. F4 : 100 mM, 1: 100 mM, cmax = 12.6 mM and
t1/2 =17 min. b. 1: 100 mM, F4 : 10 mM, cmax = 12.2 mM and t1/2 = 115 min. c. 1: 100 mM, F4 : 50 mM, cmax = 9.2 mM and t1/2 =25 min. d. 1: 5 mM, F4 :
100 mM, cmax = 4.8 mM and t1/2 =100 min.
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protease. Reducing the concentration of the dithiol DTT
increased the activity of some inhibitors considerably includ-
ing 5 and 12, while the activity of other inhibitors such as 2 was
hardly affected (see Table 1). HPLC-MS analysis of inhibitors
2, 5, and 12 with added DTT showed peaks of the unreacted
inhibitor and of inhibitor-DTT addition products. Quantifi-
cation indicated 7% of DTT-adducts with inhibitor 2, 23%
with inhibitor 5, and 87% with inhibitor 12 (Figure S7). These
results correlated with the observed weak deactivation of
compound 2 by DTT and the stronger deactivation of
compound 12.
For thermodynamic analysis, binding of inhibitors 2, 5,
and 12 was studied by isothermal titration calorimetry (ITC)
(Figure 4a,b). In order to obtain a saturated binding curve of
the inhibitors to the protein, buffer and DTT-concentration
needed to be identical in the enzyme contained in the
measurement cell and in the syringe used for adding the
concentrated ligand solution. While no binding of 12 was
Figure 3. Reversibility of antiviral protease inhibitors. a. Linear conversion of the FRET substrate over time suggested reversibility of inhibitors 2, 5
and 12. b. Dilution of assays of 2, 5 and 12 with protease from 20 W IC50 to 0.2W IC50 indicated reversible inhibition. c. Native protein MS of EV
D68 3C protease (7.5 mM) with inhibitors 2 and 5 (100 mM) in 50 mM ammonium bicarbonate buffer with 100 mM DTT, pH 8 showing protein-
inhibitor complex. d. Denaturing protein MS of EV D68 3C protease (8.2 mM) with inhibitor 12 (6.5 mM) in 100 mM HEPES buffer with 1 mM
EDTA and 10 mM DTT, pH 8, using a water-acetonitrile gradient with 0.1% formic acid. e. Saturation of protein-ligand complex with inhibitor 2
determined by native MS. Apparent KD : 16 + /@ 2.4 mM. For experimental details see Supporting Information.
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observed, inhibitors 2 and 5 displayed similar free binding
energies (DG) of @28.5 for 2 and @27.2 kJ mol@1 for 5, with
apparent affinities of 6.5 and 12.5 mM, respectively. Protein
binding of inhibitor 2 was dominated by a large negative
enthalpic contribution of DH =@50.2 kJ mol@1 and counter-
acted by a smaller positive entropic contribution of @TDS =
20.9 kJ mol@1. This entropic loss is typical for the reversible
binding of small molecules to proteins and reflects the
reduced degrees of freedom of the bound versus the free
ligand. Inhibitor 5, however, showed different, atypical bind-
ing thermodynamics with
a negative binding enthal-
py of DH =@10.5 kJmol@1
accompanied by a negative
entropy term (and, thus
positive binding entropy)
of @TDS =@16.7 kJmol@1.
We suspected that this pos-
itive binding entropy might
result from the release of
DTT from inhibitor-DTT
adducts formed at high
DTT (10 mM) as detected
above in MS. To substan-
tiate this argument, ITC
was also conducted at low
DTT concentration
(0.1 mM) resulting now in
a slightly positive entropy
term (+ 0.84 kJmol@1, see
Figure S8) and thus indi-
cating a shift to negative
binding entropy with low
DTT and less inhibitor-
DTT adduct.
Finally, reversibility
and kinetics of inhibitors
2 and 12 with the protease
were studied using biolay-
er interferometry (BLI,
Figure 4c,d).[23] For this,
the histidine-tagged 3C
protease was immobilized
on a sensor tip modified
with nickel-NTA. Loading
of the protein and binding
of inhibitors 2 and 12 were
then monitored by the
time-dependent shift of
the interference pattern of
partially reflected light.
Binding of both inhibitors
was saturated within 120 s
with association rates (kon)
in the same order of mag-
nitude (100–200 M@1 s@1).
Dissociation of both com-
pounds, however, was very
different, if monitored in
a buffer solution without additional DTT. While inhibitor 2
dissociated completely with a koff around 0.015 s
@1, only
partial dissociation of inhibitor 12 was observed. The devia-
tion from a reversible binding mode coincided with a reduced
correlation of the data fitting with the reversible 1-to-1 bind-
ing model as reported before.[23] Thus, binding kinetics
observed by BLI confirm the high stability of the protease-
ligand complex of 12 corresponding to a significantly longer
residence time of 12 compared to inhibitor 2. These findings
agree with the high stability of the protease-inhibitor complex
Figure 4. Thermodynamics and kinetics of protease-interactions for covalent inhibitors 2, 5, and 12.
a. Isothermal titration calorimetry of a solution of 2 (800 mM) added dropwise to EV D68 3C protease (60 mM)
in buffer with 10 mM DTT. Binding of 2 was driven by binding enthalpy; DG =@28.5 kJmol@1, N =1,
KD = 6.5 mM. b. ITC of 5 showed a strong entropic contribution, which was attributed to the release of DTT
from the inhibitor-DTT adduct; DG =@27.2 kJ mol@1, N =0.93, KD = 12.5 mM. c. Biolayer interferometry (BLI)
with EV D68 3C protease immobilized on an NTA-agarose chips indicated the complete reversibility of the
binding for 2 with kon-rates in the range of 100–200 M
@1 s@1 and koff-rates around 0.015 s
@1. d. Binding for 12
was characterized by significantly smaller off-rates and only partial dissociation resulting in a stronger
deviation of the fit using a reversible 1-to-1 binding model. e. Symbolic representation of the biolayer
interferometry experiment: EV D68 3C protease (grey ribbon) is attached to the sensor (grey balls and plane
indicate nickel—nitrilotriacetic acid agarose) via its His-tag (indicated as imidazole rings). The association
and dissociation of inhibitor 2 (indicated as ball and stick model) association—dissociation is recorded as
a shift in the interference pattern of visible light as a result of an alteration of the biolayer by small molecule
binding. For further details see Supporting Information.
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of 12 observed in denaturing MS and with the rapid ligand
exchange rate of 2 recorded in native protein MS and in ITC.
The relative kinetic stability of the protease-inhibitor com-
plex of 12 and its elongated residence time[24] corresponds
with higher antiviral activity of this compound in infected
cells suggesting a robust strategy for the development of
fragment-based inhibitors of viral proteases.
Conclusion
In synopsis, we have studied the chemical evolution of
antivirals in a dynamic reaction network, in which the self-
organization of building blocks led to the formation of
biochemically and cellularly active inhibitors of EV D68 3C
protease (Figure 5). Aldehyde 1 and fragment F bound
reversibly to the protein presumably forming a Zimmer-
man–Traxler transition state intermediate (reaction A) under-
going protein-catalyzed aldol addition (B) and Knoevenagel
condensation (C). The aldol product was released (D) and
eliminated water in solution, or the condensation product
dissociated into solution (E). The observed protein-catalyzed
aldol condensations constitute the first examples of protein-
templated C@C couplings leading to the formation of potent
enzyme inhibitors and antivirals. Little protein-independent
background reactions in solution were detected (A’–C’). Rate
and efficiency of inhibitor formation depended on the pH, the
CH-acidity of the C nucleophiles, the binding affinity of the
formed C@C coupling products and on the stability of the
latter toward hydration and retro-aldol reactions. Highest
rate acceleration and reactivity were found for CH-acidic
starting materials yielding inhibitors with highest affinity.
In contrast, hydration and retro-aldol reactions were
observed in solution (A’–C’ backwards) with no protein-
catalyzed acceleration (A–C backward). The formed Knoe-
venagel condensation products reacted reversibly as Michael
acceptors with thiol nucleophiles, either with the protein-thiol
of Cys147 (F) or with thiols in solution (F’). The competition
between protein thiol and DTT in solution (F versus F’)
reduced the inhibitory activity of the condensation products
in several cases (most remarkably for the diester 12).
Formation of DTT adducts in solution altered the thermody-
namics of ligand binding by reducing binding enthalpy and
enhancing the binding entropy as found for the ketone
inhibitor 5. Competition between the addition of thiol and
that of water (i.e. the hydration reaction) (F’ versus C’),
however, also inhibited the retro-aldol reaction and thus
stabilized some of the inhibitors (most remarkably the ketone
inhibitors such as 5).
The antiviral activity of the formed inhibitors depended
critically on the kinetics of the Michael addition reactions of
inhibitors with the protein target and with competing
nucleophiles present in solution. The most potent antivirals
in the cellular infection model were characterized by a ther-
modynamically stable protein-inhibitor complex with a slow
off-rate for the release of the antiviral from the protein-bound
state.
The observed formation of bioactive compounds in
a dynamic reaction network consisting of target-catalyzed
and competing reactions in solution demonstrates a mecha-
nism for the chemical evolution of drug-like molecules, which
might be exemplary for the emergence of functional mole-
cules in the early development of life. For the chemical
evolution of antivirals investigated here, the most efficient
formation of inhibitors and the highest yields were observed
for the cases of reversible C@C coupling reactions. These
findings suggest to search for dynamic reaction systems also
for the chemical evolution of other molecules with biological
activity and relevance including peptides, heterocycles and
nucleic acids.
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